The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
Mohr
Brigitte
B
Oelschlaegel
Uta
U
Thiede
Christian
C
Stewart
Michelle Meredyth
MM
Ehninger
Gerhard
G
Platzbecker
Uwe
U
D000368:Aged; D018952:Antigens, CD34 / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D020732:Cytogenetic Analysis; D005260:Female; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide